Seguir
Leif Carlsson
Leif Carlsson
PhD
Dirección de correo verificada de astrazeneca.com
Título
Citado por
Citado por
Año
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional …
WS Redfern, L Carlsson, AS Davis, WG Lynch, IL MacKenzie, ...
Cardiovascular research 58 (1), 32-45, 2003
16312003
Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic
LM Hondeghem, L Carlsson, G Duker
Circulation 103 (15), 2004-2013, 2001
5852001
QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions
L Carlsson, O Almgren, G Duker
Journal of cardiovascular pharmacology 16 (2), 276-285, 1990
2731990
Innovative approaches to anti-arrhythmic drug therapy
S Nattel, L Carlsson
Nature reviews Drug discovery 5 (12), 1034-1049, 2006
2722006
Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations
L Carlsson, C Abrahamsson, B Andersson, G Duker, G Schiller-Linhardt
Cardiovascular Research 27 (12), 2186-2193, 1993
2461993
Novel molecular targets for atrial fibrillation therapy
D Dobrev, L Carlsson, S Nattel
Nature reviews Drug discovery 11 (4), 275-291, 2012
2182012
Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?
L Carlsson, GJ Amos, B Andersson, L Drews, G Duker, G Wadstedt
Journal of Pharmacology and Experimental Therapeutics 282 (1), 220-227, 1997
2101997
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
LM Gan, M Lagerström-Fermér, LG Carlsson, C Arfvidsson, AC Egnell, ...
Nature communications 10 (1), 871, 2019
1672019
Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization.
L Carlsson, C Abrahamsson, L Drews, G Duker
Circulation 85 (4), 1491-1500, 1992
1621992
Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine
L Carlsson, JC Clarke, C Yen, F Gregoire, T Albery, M Billger, AC Egnell, ...
Molecular Therapy-Methods & Clinical Development 9, 330-346, 2018
1442018
Protective effects of ticagrelor on myocardial injury after infarction
G Vilahur, M Gutiérrez, L Casani, L Varela, A Capdevila, G Pons-Lladó, ...
Circulation 134 (22), 1708-1719, 2016
1372016
Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile …
RN Goldstein, C Khrestian, L Carlsson, AL Waldo
Journal of cardiovascular electrophysiology 15 (12), 1444-1450, 2004
1192004
Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey
TG Hammond, L Carlsson, AS Davis, WG Lynch, I MacKenzie, ...
Cardiovascular Research 49 (4), 741-750, 2001
1172001
Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing
N Sun, B Ning, KM Hansson, AC Bruce, SA Seaman, C Zhang, M Rikard, ...
Scientific reports 8 (1), 17509, 2018
922018
In vitro and in vivo models for testing arrhythmogenesis in drugs
L Carlsson
Journal of internal medicine 259 (1), 70-80, 2006
912006
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation
A Burashnikov, JM Di Diego, S Sicouri, M Ferreiro, L Carlsson, ...
Heart Rhythm 5 (12), 1735-1742, 2008
902008
Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant
C Abrahamsson, M Palmer, B Ljung, G Duker, C Bäärnhielm, L Carlsson, ...
Cardiovascular research 28 (3), 337-344, 1994
821994
Blocking characteristics of hERG, hNav1. 5, and hKvLQT1/hminK after administration of the novel anti‐arrhythmic compound AZD7009
F Persson, L Carlsson, G Duker, I Jacobson
Journal of cardiovascular electrophysiology 16 (3), 329-341, 2005
752005
Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit
I Jacobson, L Carlsson, G Duker
Journal of pharmacological and toxicological methods 63 (1), 40-46, 2011
652011
Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre
F Persson, B Andersson, G Duker, I Jacobson, L Carlsson
European journal of pharmacology 558 (1-3), 133-143, 2007
632007
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20